PAN-TB XBQS Trial

Submitted by zaidtanvir on

Known as "PAN-TB XBQS" for the two regimens being evaluated (PBQS & DBQS), this multicenter, two-stage, open-label, randomized trial will aim to assess the efficacy, safety, optimal duration, and pharmacokinetics (PK) of Delamanid, Bedaquiline, Quabodepistat (previously OPC-167832), and Sutezolid (DBQS) and Pretomanid, Bedaquiline, Quabodepistat, and Sutezolid (PBQS) in adult participants with drug sensitive tuberculosis (DS-TB) and rifampicin or multi-drug resistant TB (RR/MDR-TB).

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Submitted by barbara on

This is a 2-part blinded, placebo-controlled, combined single ascending dose with a food effect cohort and multiple ascending dose trial to be conducted in one trial center in the United States.

Part 1 has a single ascending dose (SAD) design with up to 5 planned dose levels. Based on the interim PK results reviewed for the dose escalation decisions, a dose will be selected for administration to a sixth cohort both in fed and fasted states to evaluate the effect of food on MK-7762 (TBD09).

Pages

Subscribe to Working Group for New TB Drugs RSS